HealthTech HALO Effect: Heavy Assets, Low Obsolescence in the Healthcare AI Era

Nelson Advisors
2 hours ago
15 min read

The global financial landscape in early 2026 has witnessed a profound structural shift, characterised by a transition from the speculative, capital-light growth models of the early 2020s toward a strategy centered on tangible infrastructure and physical resilience. This phenomenon, which market analysts have termed the Great Recalibration, marks the end of an era dominated by "silicon dreams" and the beginning of a period rooted in "industrial reality".

At the heart of this transition is the emergence of the HALO effect, an investment and operational framework standing for Heavy Assets and Low Obsolescence. This paradigm prioritises companies that possess significant physical capital, specialised manufacturing capabilities, and entrenched infrastructure, assets that are increasingly viewed as the only durable moats against the disruptive and commoditising power of generative artificial intelligence and large language models.

The Structural Pivot: From Silicon Dreams to Industrial Reality

The narrative of the 2020s bull market was initially driven by the ethereal promise of software-driven disruption. However, as 2025 gave way to 2026, the market entered a maturing phase where the initial euphoria surrounding AI began to face the harsh scrutiny of return-on-investment requirements. Investors who had previously poured capital into any entity with an AI label began to recognise a fundamental truth: while software can be replicated or made obsolete by a superior algorithm overnight, physical assets like high-density power grids, specialised pharmaceutical manufacturing plants, and complex medical device networks are inherently difficult to displace. This realisation triggered what some have called the "AI immunity trade," a movement toward "HALO" stocks that are perceived as less vulnerable to technological upheaval.

Defining the HALO Paradigm

The HALO framework was popularised by strategists at major financial institutions, including Goldman Sachs and Ritholtz Wealth, to describe a new class of defensive stocks. These companies are defined by their reliance on physical infrastructure and tangible goods, which serve as a natural barrier to entry that software-based automation cannot shortcut.The core philosophy suggests that in an economy where intelligence is becoming a cheap, abundant commodity, the value of the "analog" world, the physical capacity to produce, distribute and provide complex manual services, re-emerges as the ultimate source of scarcity and pricing power.

Within the healthcare sector, the HALO effect is manifesting as a renewed appreciation for "heavy" entities: biopharmaceutical giants with massive R&D pipelines, medtech firms with precision hardware, and care delivery organisations with extensive physical footprints. These organisations are less exposed to the "white-collar bloodbath" predicted by some researchers, where AI agents replace software developers, tax preparers, and legal researchers. Instead, these firms use AI to augment their heavy assets, driving higher returns on invested capital without risking the obsolescence of their core value proposition.

The Macroeconomic Catalyst: The Warsh Shock and OBBBA

The acceleration of the HALO trade in early 2026 was not a spontaneous event but was precipitated by significant macroeconomic and policy shifts. A pivotal moment occurred in late January 2026 with the "Warsh Shock", the nomination of Kevin Warsh as the Federal Reserve Chair. Known for his hawkish stance on monetary discipline, Warsh’s arrival signaled an end to the "Fed Put" for speculative growth companies that relied on cheap capital. This forced a rapid recalibration of valuations across the tech sector, leading to a 31% discount in "unloved" value sectors compared to tech giants.

Simultaneously, the legislative environment provided a tailwind for asset-heavy businesses through the "One Big Beautiful Bill Act" (OBBBA) passed in late 2025. By making corporate tax cuts permanent for domestic manufacturers and providing incentives for industrial expansion, OBBBA essentially subsidised the "Heavy Asset" side of the HALO equation. This policy environment favored the industrialization of healthcare, where the focus shifted from digital health apps to the domestic manufacturing of critical drugs and the expansion of physical hospital capacity.

Policy/Event	Date	Primary Market Impact	Sector Beneficiaries
OBBBA Legislation	Late 2025	Permanent tax cuts for domestic manufacturing	Industrials, MedTech, CDMOs
Warsh Shock	Jan 2026	End of speculative growth "Fed Put"	Value, Energy, Defensive Healthcare
AI Capex Fatigue	Feb 2026	Demand for proof of AI ROI	Infrastructure, Logistics, Equipment
OBBBA Rollout	H1 2026	Capital reallocation to physical moats	Utilities, Materials, Healthcare Services

Quantitative Moats: The HALO Metrics Framework

To identify companies that truly fit the HALO criteria, institutional investors have adopted a specific quantitative filter that moves beyond traditional sector classifications. This framework relies on the intersection of physical durability and labor efficiency, creating a two-dimensional map of disruption risk.

Labour to Revenue and Physical Asset Density

The first critical metric in the HALO filter is physical asset density, which measures the concentration of tangible, high-replacement-cost infrastructure within a firm’s business model. Companies with factories, distribution networks, or specialised medical labs carry a natural moat because these operations take years, if not decades, to replicate. In the context of the AI era, this physical density is a protection against "software envy", the risk that a digital competitor could use AI to recreate a service platform overnight.

The second metric is the labor-cost-to-revenue ratio, which assesses a company’s exposure to AI-driven margin compression. Businesses that are heavily dependent on high-cost human labor for cognitive tasks, such as traditional asset managers, software providers, and certain professional services, are viewed as being on the "wrong side" of the disruption divide. Conversely, firms that maintain a low labour to revenue ratio or whose labour is primarily physical and manual (eg. manufacturing line workers or specialized surgeons) are considered more durable.

HALO Metric	High Resilience (Defensive)	High Risk (Vulnerable)
Physical Asset Density	High: CDMOs, MedTech Hardware, Clinics	Low: SaaS, Digital Health, AI Apps
Labor-to-Revenue	Low: Highly automated manufacturing	High: Consulting, Manual Data Entry
Replacement Cost	Extremely High: Regulated physical sites	Low: Cloud-based digital platforms
Obsolescence Risk	Low: Physical goods/services remain essential	High: AI can automate core intellectual tasks

The "AI Immunity" Trade: A Repricing of Competitive Durability

The market’s reaction to these metrics has been swift and decisive. In early February 2026, the unveiling of advanced agentic AI tools by firms like Anthropic triggered a $300 Billion selloff in software, financial data, and exchange operators. Investors began to fear that "enterprise software moats" were being bridged by AI, rendering legacy business models obsolete. This prompted a rotation into "AI-resistant" sectors like energy, materials, and industrials, which have outperformed the broader S&P 500.

Within healthcare, this repricing has created a "two-speed" market. "A" assets, those with differentiated physical pipelines, such as oncology and CNS therapies, or mission-critical hardware, command premium multiples. Meanwhile, labor-intensive healthcare services that lack physical differentiation or are heavily sensitive to government reimbursement face widening bid-ask spreads and significant valuation discounts.

Biopharmaceutical Moats: Scarcity and Manufacturing Complexity

The biopharmaceutical industry represents the pinnacle of the HALO paradigm, combining massive capital requirements with extremely low rates of technological obsolescence for approved, life-saving therapies. In 2026, the sector’s resilience is increasingly tied to the scarcity of manufacturing capacity and the biological complexity of its products.

CDMO Capacity as Strategic Gold: The Novo/Catalent Precedent

The strategic importance of physical manufacturing capacity has been highlighted by the surge in demand for GLP-1 (obesity and diabetes) treatments. The landmark acquisition of Catalent by Novo Holdings for approximately $16.5 Billion serves as the primary case study for the "Manufacturing HALO". This transaction was driven not by the desire to acquire new drug intellectual property, but by the urgent need to secure "fill-finish" capacity and supply-chain resilience.

In an era of geopolitical fragmentation and supply chain restructuring, owning the means of production has become a critical competitive advantage. Pharmaceutical manufacturing is characterised by high barriers to entry, including stringent regulatory oversight and the requirement for specialized engineering expertise that AI systems cannot replicate through digital simulation alone. As a result, Contract Development and Manufacturing Organisations (CDMOs) are being revalued as essential infrastructure rather than mere service providers.

De-risking the Pipeline: Strategic M&A in CNS and Metabolic Diseases

M&A activity in early 2026 has focused on acquiring de-risked, late-stage assets that provide a buffer against the "patent cliffs" facing major pharmaceutical companies. The Johnson & Johnson acquisition of Intra-Cellular Therapies for $14.6 Billion reinforced the market’s appetite for differentiated Central Nervous System (CNS) assets.

These therapies represent a physical and biological moat because the underlying science is complex, the clinical trial process is lengthy, and the regulatory pathway is arduous, factors that preserve the asset's value even in a rapidly changing technological landscape.

High-Signal Deal (2025-2026)	Transaction Value	Strategic Asset Category	Primary Driver
Novo Holdings / Catalent	~$16.5B	Manufacturing / CDMO	Supply chain control, GLP-1 capacity
J&J / Intra-Cellular	~$14.6B	Biopharma / CNS	Differentiated late-stage pipeline
Pfizer / Metsera	Up to ~$10B	Biopharma / Obesity	Strategic metabolic category entry
Boston Scientific / Penumbra	~$14.5B	MedTech Hardware	Interventional platform consolidation

Medical Technology and Robotics: The Physicality of Precision

The MedTech industry has emerged as a major beneficiary of the HALO trend, as hospitals and healthcare providers prioritise technologies that enhance clinical outcomes while improving operational efficiency. In 2026, the sector is moving past prior supply-chain and labour constraints, with procedure volumes normalizing and elective surgery backlogs easing.

Robotic Surgery and the Barrier of Hardware Integration

Companies like Intuitive Surgical (ISRG) and Medtronic (MDT) are quintessential HALO entities because their competitive advantage is anchored in complex physical hardware and a massive installed base. Robotic surgery adoption continues to expand worldwide as providers seek to enhance precision and efficiency. Intuitive Surgical’s robotic systems are not just tools but integrated platforms that include specialized instruments and comprehensive clinician training programs, creating high switching costs that protect against disruption.

Medtronic is similarly advancing its "Hugo" robotic surgery system and pulsed field ablation (PFA) technologies. These innovations represent "Heavy Assets" that require significant R&D investment and physical manufacturing precision.While AI is used within these systems to assist in surgical planning and real-time guidance, the core value proposition remains the physical intervention, which cannot be automated by software alone.

AI as an Augmentation Layer: Case Studies in Respiratory Imaging

In the MedTech sector, AI is being deployed as an augmentation layer that increases the value of physical diagnostic hardware. A prime example is 4DMedical’s AI-driven respiratory imaging, which was recently adopted by tier-one US institutions like the Cleveland Clinic. This technology addresses the critical shortage of radiologists by providing automated, high-speed diagnostic insights that streamline clinical workflows.

The success of these tools demonstrates that the "AI trade" is becoming highly discriminatory. Investors are no longer rewarding AI for AI's sake; they are rewarding AI that is integrated into "embedded operational ecosystems" and hardware platforms. This hardware-software synergy creates a recurring revenue model (SaaS) that is attractive to investors seeking predictable cash flows in a volatile market.

MedTech Company	Key Innovation/Asset	HALO Characteristic	2026 Outlook
Intuitive Surgical (ISRG)	Da Vinci / Robotics	Massive installed base, high switching cost	Continued procedural growth
Medtronic (MDT)	Hugo / PFA Systems	Diversified platform, physical precision	Margin improvement, pipeline advances
4DMedical	XV Technology / AI	Software-hardware diagnostic integration	Rapid US clinical adoption
Cardinal Health (CAH)	Pharma/Medical Supply	Physical logistics and distribution network	Disciplined cost and volume recovery

The Industrialisation of Care Delivery: Logistics as a Clinical Moat

One of the most significant shifts in healthcare delivery is the move toward "industrialised care," where logistics, physical networks, and supply chain control become the primary drivers of patient outcomes. This trend is most clearly seen in the strategies of major retail and technology players who are using their "Heavy Assets" to disrupt traditional primary care.

Amazon Healthcare: The Prime Halo Effect and Same Day Delivery

Amazon’s entry into healthcare is predicated on its unparalleled logistical infrastructure and the loyalty of the Amazon Prime membership program. By the end of 2026, Amazon plans to triple the size of its delivery network, with a focus on extending same-day and next-day pharmacy delivery into smaller cities and rural communities. This physical reach serves as a "Prime Halo Effect," facilitating customer acquisition and improving clinical outcomes through better patient adherence to medication regimens.

In the framework of Value-Based Care (VBC), improved adherence directly translates into a quantifiable reduction in the total cost of care. By transforming its fulfillment centers into "clinical outcome enablers," Amazon is creating a durable moat that virtual-only healthcare providers cannot replicate. This physical dominance allows Amazon to potentially transition into underwriting patient populations, as the predictability of its logistics-driven outcomes lowers the risk of health insurance contracts.

Hybrid Care Models: One Medical and the Physical Presence Advantage

The integration of One Medical into Amazon’s ecosystem further exemplifies the HALO strategy. Unlike pure telehealth startups that struggled in the high-rate environment of 2025, One Medical offers a comprehensive hybrid model with over 200 physical offices and 24/7 virtual care. This physical presence is critical for establishing trust and managing the "primary care referral stream" for major hospital systems like the Cleveland Clinic and Hackensack Meridian Health.

While Amazon utilises generative AI via "Amazon Bedrock" to automate clinical documentation and summarise patient records, this technology is treated as a secondary efficiency tool designed to address provider burnout. The primary competitive differentiator remains the physical office network and the logistical speed of the pharmacy delivery system.

Digital Pathology and Diagnostics: Scaling the Human Bottleneck

Digital pathology is perhaps the most hardware-intensive segment of the modern diagnostic landscape, making it a natural fit for the HALO investment thesis. The global market for whole slide imaging (WSI) systems is projected to grow significantly as laboratories digitise their workflows to cope with a mounting global cancer burden and a chronic shortage of pathologists.

Whole Slide Imaging: The High-Throughput Hardware Revolution

Whole slide imaging involves scanning traditional glass slides to create high-resolution digital images that can be analysed by pathologists and AI tools. This technology is hardware-heavy, requiring sophisticated scanners capable of processing hundreds of slides per run. In early 2026, firms like Agilent and Leica Biosystems launched new high-throughput scanners to address rising laboratory volumes in Europe and North America.

These scanners are "Heavy Assets" that require significant capital expenditure for installation and maintenance. However, they offer a low rate of obsolescence because they provide the fundamental data layer—the high-resolution image, that is necessary for all subsequent digital analysis. The market for WSI systems is expected to reach $0.98 billion in 2026, driven by advancements in digital pathology integration and the increasing use of telepathology for remote consultations.

AI in Pathology: Enhancing Sensitivity and Clinical Throughput

The role of AI in digital pathology is to serve as a clinical decision support system that accelerates the diagnostic process.AI solutions can analyse tissues to spot disease presence that may be missed by the human eye, with some studies showing an 82% gain in accuracy and a 90% reduction in the time required to detect metastatic deposits.

Importantly, AI in this context is viewed as a tool that "dramatically augments" the capabilities of pathologists rather than replacing them. Given that it takes 5 to 10 years of practice to build the experience necessary for a pathologist to operate at speed, AI-powered solutions like those from Roche and Leica provide a way to scale diagnostic access without needing to wait for a new generation of human experts.

WSI Market Metric	2025 (Estimated)	2026 (Forecast)	2033 (Projected)
Global Market Size	$0.88 Billion	$0.98 Billion	$1.48 Billion
Growth Rate (CAGR)	7.4% (Historical)	12.1% (Forecast)	10.7% (2026-2033)
Key Growth Driver	Cancer prevalence	AI tool integration	Workflow automation
Leading Geography	North America	Europe (High growth)	Asia-Pacific (Fastest)

The New Era of Health Information Systems

The "Heavy Asset" philosophy is even reshaping the world of Health Information Technology (HCIT), where dominant electronic health record (EHR) providers are using their entrenched infrastructure to deploy AI at scale.

Generative Intelligence in EHRs: Epic's Art and Curiosity Models

Epic, the nation’s leading EHR provider, has moved aggressively to integrate generative AI into its clinical workflows through its "Art" and "Curiosity" model families. These tools are designed to reduce the administrative burden on clinicians, a major cause of burnout, by drafting end-of-shift notes and summarizing patient charts. Epic research indicates that these AI models allow nurses to write notes up to 85% faster.

The competitive moat for Epic is not the AI model itself, but the "Heavy Asset" of the EHR platform, which is integrated into thousands of hospitals and used by millions of patients. Transitioning between EHR systems is a decade-long, multi-billion-dollar endeavor (as seen in Trinity Health’s $80 million migration savings), which creates a "Low Obsolescence" environment for the incumbent. In early 2026, Epic’s "Curiosity" models are set to transform how clinicians predict and manage patient outcomes, reinforcing the platform’s role as the central nervous system of the hospital.

Reducing Clinician Burnout through Ambient Intelligence

The impact of these AI integrations is reflected in tangible clinical outcomes and operational savings. For example, Baptist Health used Epic's MyChart Care Companion for remote patient management, resulting in an average systolic blood pressure decrease of 10-11 mmHg in hypertensive patients, an effect comparable to adding a new medication.Similarly, Legacy Health utilised standardisation and predictive modelling in Epic to reduce inpatient length of stay by more than a full day, freeing up 50,000 bed days and saving $54 Million. These successes demonstrate that when AI is paired with high-switching-cost infrastructure, it becomes a powerful multiplier of asset value.

Investment Strategies and Tactical Portfolio Management

As the market enters the second quarter of 2026, the HALO strategy has evolved from a defensive crouch into a proactive tactical framework for portfolio management. Investors are increasingly utilizing a "barbell" approach to balance the risks of the AI era.

The Barbell Strategy: Balancing AI Compounders with HALO Ballast

The barbell strategy involves maintaining positions in "proven AI compounders", large-cap technology firms that provide the fundamental computing infrastructure for AI, while adding "HALO ballast" in the form of cash-rich, durable businesses in sectors like healthcare, energy, and industrials. This approach acknowledges that while AI will continue to create winners at the edge of software, the "core of the physical economy" that provides power, transport, and clinical care remains the most reliable source of compounded returns.

Tactical portfolio moves in 2026 prioritise names with high free cash flow (FCF) yields and disciplined capital returns through dividends and buybacks. Management confidence is increasingly measured by the consistency of these returns, rather than by ambitious growth promises that may be disrupted by the next technological cycle.

Financial Discipline: FCF Yields and ROCE in a High-Rate Environment

The Great Recalibration has returned the market's focus to foundational financial metrics. In a world where interest rates are no longer "cheap," investors are rewarding firms that earn consistently above their cost of capital (ROCE vs. WACC).HALO stocks often trade at more reasonable valuations than their tech counterparts, allowing for a "re-rating" as the market recognises their inherent durability.

Investment Signal	Positive for HALO Trade	Negative for HALO Trade
AI Infrastructure Capex	Rising (boosts power/equipment demand)	Falling (signals AI exhaustion)
Software Margins	Compressing (confirms obsolescence risk)	Expanding (suggests durable digital moats)
Interest Rates	Staying above "easy money" levels	Returning to near-zero levels
Dividend/Buyback Activity	Stable or rising (shows management confidence)	Suspended (signals balance sheet stress)

The Human Element: Bias and the Integration of Intelligence

As healthcare organisations integrate AI into their "Heavy Assets," the human factors that determine the effectiveness of these systems have come to the forefront. The potential for cognitive bias to distort AI outcomes is a significant concern for 2026, as the "halo and horns" effects can infiltrate every stage of human-AI collaboration.

The Cognitive HALO and Horns Effects in AI Interaction

In the context of behavioural psychology, the "halo effect" refers to a user's tendency to assume an AI system is broadly reliable because of a single positive experience. Conversely, the "horns effect" leads to unwarranted skepticism after a high-profile failure. If clinicians view AI through a halo effect, they may accept outputs from a diagnostic tool without sufficient evaluation, potentially leading to medical errors.

Research has documented that human-AI feedback loops can amplify these biases over time, creating "echo chambers" where bad assumptions go unchallenged. To mitigate this risk, healthcare organisations are investing in "responsible AI" initiatives that emphasise intention, systematic oversight, and the right "systems of interaction" to ensure that AI remains a true partner in clinical decision-making.

Accountability and the Future of Decision Support

The shift toward outcome-based technology consumption is forcing a new discussion around accountability. When AI produces a flawed or biased result, organizations can no longer simply blame the algorithm or the training data. Instead, they must examine the human factors—such as confirmation bias or expediency bias—that led to the selective acceptance of that output.

In the surgical and oncology fields, "HALO Intelligence" platforms are being designed to provide real-time clinical decision support by integrating patient data with evidence-based knowledge at the point of care. These systems aim to design personalized care plans across the entire patient journey, from diagnosis to follow-up, ensuring that innovation benefits all patients while managing the stress and uncertainty inherent in modern clinical practice.

Nuanced Conclusions and the Road Ahead

The emergence of the HealthTech HALO effect in early 2026 is a definitive sign of a maturing global economy that is re-learning the value of the tangible. As large language models commoditise the generation of text, code, and basic insights, the competitive frontier has moved to the "physical bottleneck, the specialised manufacturing plant that can produce a biological drug, the high-throughput scanner that can digitise a thousand pathology slides, and the logistical network that can deliver medical supplies to a patient’s home in hours.

For healthcare investors and executives, the HALO paradigm offers a roadmap for navigating the "AI-pocalypse" feared by some market participants. By prioritising "Heavy Assets" with high replacement costs and "Low Obsolescence" risk, firms can insulate themselves from the volatility of the digital world. The winners of the 2026 era will be those that treat technology not as a standalone feature, but as the foundation of an integrated physical thesis—using intelligence to maximize the throughput of capacity that is too costly for any competitor to replicate.

The path forward will be defined by a "Shift from Virtual to Real," as global capital continues to embrace sectors with physical moats and domestic manufacturing advantages. In this landscape, the HALO effect is not merely a psychological bias, but a strategic imperative that recognises the enduring power of infrastructure in an increasingly automated world. The Great Recalibration is still in its early stages, but the trend is clear: in the healthcare AI era, the most durable "halo" is the one cast by heavy, irreplaceable physical assets.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech